Last updated: July 6, 2026
Bristol-Myers Squibb Co. v. Apotex Inc. (3:10-cv-05810): Litigation Summary, Patent Issues, and Exclusivity Impact
Bristol-Myers Squibb Company v. Apotex, Inc., Case No. 3:10-cv-05810, is a U.S. patent litigation brought in the wake of Apotex seeking FDA approval for a generic product aligned to a Bristol-Myers Squibb (BMS) innovator drug. The record in the case docket is required to produce a complete, accurate litigation summary, including asserted patent numbers, claims, Paragraph IV certifications, and any settlement or final judgment terms.
No docket content (complaint, claim list, patent numbers, FDA ANDA reference, Markman orders, dispositive rulings, or settlement documents) was provided, so a reliable litigation summary cannot be generated.
What patents were asserted in BMS v. Apotex 3:10-cv-05810?
A complete answer requires the asserted patent list from the complaint and/or the court’s claim chart or pretrial order. Without the patent numbers and asserted claims, the patent-issue analysis cannot be produced.
Which Bristol-Myers Squibb patents were listed?
Patent identifiers (US publication/application numbers and granted patent numbers), ownership and assignees, and asserted independent/dependent claims are needed.
Were method-of-use, formulation, or formulation-process patents in play?
That determination requires the patent titles/claims and the specific infringement theory in the pleadings.
What Orange Book patents did Apotex challenge via Paragraph IV in 3:10-cv-05810?
To identify the Orange Book basis, the analysis must map:
- the ANDA product and listed reference listed drug (RLD)
- the Orange Book “listed patents” for that RLD at the time of filing
- the Paragraph IV “certification(s) as to invalidity and non-infringement” corresponding to those listed patents
No ANDA/Orange Book listing details were provided.
What was the litigation timeline for 3:10-cv-05810 (filing, motions, Markman, and rulings)?
A timeline requires docket entries such as:
- complaint filing date and service
- answers and counterclaims
- claim construction (Markman) schedule and order
- summary judgment or dismissal rulings
- trial dates and outcomes or settlement dates
No docket events were provided.
How did claim construction and dispositive motions affect infringement and validity in 3:10-cv-05810?
Claim construction outcomes (construction of key terms, scope limits, and means-plus-function interpretations) drive invalidity and infringement. Without the Markman order or motion rulings, no legal-strength analysis can be stated.
Was there a settlement in BMS v. Apotex 3:10-cv-05810, and what were the launch/earliest expiration terms?
Settlement analysis requires:
- settlement date
- whether there was a covenant not to sue
- time-to-market restrictions (e.g., agreed launch dates or exclusivity carve-outs)
- patent licenses or pay terms (if any)
No settlement record was provided.
When does exclusivity end for the BMS product at issue, and how does 3:10-cv-05810 change generic entry risk?
To answer exclusivity timing, the analysis must know:
- the drug and RLD
- regulatory exclusivities (NCE, pediatric exclusivity, orphan exclusivity, 5-year/3-year protections)
- patent expiration dates and any pediatric-extension dates
- any court-imposed stay or settlement launch dates
Without the drug identity and patent list, exclusivity timing cannot be computed.
How many patents covered the BMS drug in this litigation, and what is the patent estate strength?
Patent estate strength requires:
- count of listed/ asserted patents
- remaining life per patent (expiration including adjustments and extensions)
- linkage to the product and formulation/dosage form
- remaining validity risk after any court rulings
No asserted or listed patents were provided.
Which generic entry scenarios existed after the lawsuit in 3:10-cv-05810 (full launch vs. design-around vs. carve-out)?
Scenario planning depends on:
- which claims/patents were dismissed or found invalid
- what design-around constraints were negotiated or imposed
- FDA approval status and labeling outcomes
- any dismissal language narrowing infringement theories
No case outcome details were provided.
What is the FDA status and ANDA posture tied to this case?
A complete FDA regulatory linkage needs:
- ANDA number
- FDA approval status (tentative approval vs approval)
- eligibility for a 30-month stay under 35 U.S.C. § 271(e)(4)
- labeling and exclusivity-relevant milestones
No ANDA information was provided.
Does this case indicate biosimilar or biologics-style risk (or is it small-molecule only)?
This depends on the drug class. No drug identity was provided.
How does BMS’s patent position in 3:10-cv-05810 compare with other Apotex paragraph IV litigations?
Comparative analysis requires:
- other Apotex cases with similar RLDs or same portfolio
- outcomes and whether Apotex settled or lost
- relative strength measured by upheld patents or settlement terms
No comparative case data was provided.
Key Takeaways
- Cannot produce an accurate litigation summary for Bristol-Myers Squibb Company v. Apotex, Inc. (3:10-cv-05810) without the case docket record detailing the asserted patents, claim construction, motion rulings, and final outcome/settlement terms.
- Patent and Orange Book mapping cannot be performed without the drug identity and the asserted/listed patent numbers.
FAQs
- What asserted patents does BMS list in 3:10-cv-05810?
- Which Orange Book listed patents correspond to the Paragraph IV certifications in this case?
- Did any Markman order narrow the claim scope or dispose of key terms in 3:10-cv-05810?
- Was a 30-month stay entered, and when did it end under 35 U.S.C. § 271(e)(4)?
- What earliest possible generic launch date results from the final judgment or settlement terms?
References (APA)
- (No cited sources available because no docket, complaint, orders, or FDA filings were provided.)
